The efficacy of combination chemotherapy including intraperitoneal cisplatinum and mitoxantrone with intravenous ifosfamide in patients with FIGO stage IC ovarian carcinoma

Abstract

Objective: Patients With stage I ovarian cancer show a high incidence of recurrent disease ranging from 30% to 50% which may be associated with ii shortened survival. Therefore. a subset of early-stage patients with poor prognostic factors who are most likely to present with recurrent disease in the next few years may benefit from adjuvant treatment.